Jacek Otlewski

Wroclaw, DS 50383, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 73 publications

Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes.

Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes.

Journal: Molecular biomedicine

Published: July 20, 2025

Targeting HER2 and FGFR-positive cancer cells with a bispecific cytotoxic conjugate combining anti-HER2 Affibody and FGF2.

Targeting HER2 and FGFR-positive cancer cells with a bispecific cytotoxic conjugate combining anti-HER2 Affibody and FGF2.

Journal: International journal of biological macromolecules

Published: August 03, 2023

Correction: Galectins use N-glycans of FGFs to capture growth factors at the cell surface and fine-tune their signaling.

Correction: Galectins use N-glycans of FGFs to capture growth factors at the cell surface and fine-tune their signaling.

Journal: Cell communication and signaling : CCS

Published: June 13, 2023

Intracellular FGF1 protects cells from apoptosis through direct interaction with p53.

Intracellular FGF1 protects cells from apoptosis through direct interaction with p53.

Journal: Cellular and molecular life sciences : CMLS

Published: May 21, 2023

Dual-Warhead Conjugate Based on Fibroblast Growth Factor 2 Dimer Loaded with α-Amanitin and Monomethyl Auristatin E Exhibits Superior Cytotoxicity towards Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1.

Dual-Warhead Conjugate Based on Fibroblast Growth Factor 2 Dimer Loaded with α-Amanitin and Monomethyl Auristatin E Exhibits Superior Cytotoxicity towards Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1.

Journal: International journal of molecular sciences

Published: May 12, 2023

FGF1 Protects MCF-7 Cells against Taltobulin through Both the MEKs/ERKs and PI3K/AKT Signaling Pathway.

FGF1 Protects MCF-7 Cells against Taltobulin through Both the MEKs/ERKs and PI3K/AKT Signaling Pathway.

Journal: Biomedicines

Published: May 08, 2023

N-glycosylation acts as a switch for FGFR1 trafficking between the plasma membrane and nuclear envelope.

N-glycosylation acts as a switch for FGFR1 trafficking between the plasma membrane and nuclear envelope.

Journal: Cell communication and signaling : CCS

Published: March 24, 2023

Short report galectins use N-glycans of FGFs to capture growth factors at the cell surface and fine-tune their signaling.

Short report galectins use N-glycans of FGFs to capture growth factors at the cell surface and fine-tune their signaling.

Journal: Cell communication and signaling : CCS

Published: January 25, 2023

Receptor clustering by a precise set of extracellular galectins initiates FGFR signaling.

Receptor clustering by a precise set of extracellular galectins initiates FGFR signaling.

Journal: Cellular and molecular life sciences : CMLS

Published: January 19, 2023

Multivalent protein-drug conjugates - An emerging strategy for the upgraded precision and efficiency of drug delivery to cancer cells.

Multivalent protein-drug conjugates - An emerging strategy for the upgraded precision and efficiency of drug delivery to cancer cells.

Journal: Biotechnology advances

Published: December 28, 2022

FGF12 is a novel component of the nucleolar NOLC1/TCOF1 ribosome biogenesis complex.

FGF12 is a novel component of the nucleolar NOLC1/TCOF1 ribosome biogenesis complex.

Journal: Cell communication and signaling : CCS

Published: August 25, 2022

FGF1 protects FGFR1-overexpressing cancer cells against drugs targeting tubulin polymerization by activating AKT via two independent mechanisms.

FGF1 protects FGFR1-overexpressing cancer cells against drugs targeting tubulin polymerization by activating AKT via two independent mechanisms.

Journal: Frontiers in oncology

Published: August 04, 2022

Showing 1-12 of 73

Last Updated: 09/26/2026